Physician profile
Kunal Grover
NPI 1346445574
$5,086.01
in general payments reported to CMS, 2019-2025
37 companies · $955 in 2025
The $955 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $775 · 2020: $461 · 2021: $479 · 2022: $668 · 2023: $437 · 2024: $1,311 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,703.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $758.04 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $708.27 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $640.54 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $452.81 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $391.03 | 2019-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $388.87 | 2019-2024 | Livdelzi |
| Celgene Corporation | $203.13 | 2021-2024 | Zeposia |
| Pfizer INC. | $196.87 | 2019-2025 | |
| Cumberland Pharmaceuticals, INC. | $154.98 | 2019-2020 | |
| Lilly USA, LLC | $126.58 | 2023-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $114.59 | 2020-2024 | Ocaliva |
| Merck Sharp & Dohme LLC | $112.74 | 2020-2023 | |
| Qol Medical, LLC | $69.82 | 2021-2023 | Sucraid |
| Daiichi Sankyo INC. | $69.15 | 2020-2022 | |
| Shionogi INC | $68.13 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $64.16 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $60.07 | 2022-2024 | Ibsrela |
| Celltrion USA INC. | $52.00 | 2025 | Vegzelma |
| Aimmune Therapeutics, INC. | $51.12 | 2025 | Zenpep |
| Braintree Laboratories, INC. | $50.41 | 2021-2025 | Suflave |
| Vivus LLC | $46.33 | 2019-2020 | |
| Ethicon US, LLC | $33.29 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $32.89 | 2024-2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $30.88 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $30.20 | 2022-2023 | Dupixent |
| Ferring Pharmaceuticals INC. | $27.13 | 2019-2023 | Rebyota |
| Alnylam Pharmaceuticals INC. | $18.96 | 2020 | |
| Blueprint Medicines Corporation | $17.14 | 2024 | Ayvakit |
| Medtronic, INC. | $15.64 | 2022 | |
| Novo Nordisk INC | $14.93 | 2025 | Wegovy |
| Alexion Pharmaceuticals, INC. | $14.19 | 2019 | |
| Redhill Biopharma INC. | $14.16 | 2020 | |
| Amag Pharmaceuticals, INC. | $13.87 | 2019 | |
| Boston Scientific Corporation | $13.82 | 2021 | |
| Ironwood Pharmaceuticals, INC | $11.63 | 2019 | |
| Allergan, INC. | $11.33 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $6.31 | 2024 | Lesionhunter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kunal Grover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.